These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 30815083)

  • 1. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
    Fialoke S; Malarstig A; Miller MR; Dumitriu A
    AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
    Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
    Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
    Sterling RK; Smith PG; Brunt EM
    J Clin Gastroenterol; 2013 Feb; 47(2):182-7. PubMed ID: 23059409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
    Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
    Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men.
    Kim JK; Chon NR; Lim HC; Lee KS; Han KH; Chon CY; Park YN; Paik YH
    J Gastroenterol Hepatol; 2012 Jan; 27(1):142-8. PubMed ID: 21883454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.
    Kornek M; Lynch M; Mehta SH; Lai M; Exley M; Afdhal NH; Schuppan D
    Gastroenterology; 2012 Aug; 143(2):448-58. PubMed ID: 22537612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.